Literature DB >> 29601253

The current status, challenges, and future developments of new tuberculosis vaccines.

Wenping Gong1, Yan Liang1, Xueqiong Wu1.   

Abstract

Mycobacterium tuberculosis complex causes tuberculosis (TB), one of the top 10 causes of death worldwide. TB results in more fatalities than multi-drug resistant (MDR) HIV strain related coinfection. Vaccines play a key role in the prevention and control of infectious diseases. Unfortunately, the only licensed preventive vaccine against TB, bacilli Calmette-Guérin (BCG), is ineffective for prevention of pulmonary TB in adults. Therefore, it is very important to develop novel vaccines for TB prevention and control. This literature review provides an overview of the innate and adaptive immune response during M. tuberculosis infection, and presents current developments and challenges to novel TB vaccines. A comprehensive understanding of vaccines in preclinical and clinical studies provides extensive insight for the development of safer and more efficient vaccines, and may inspire new ideas for TB prevention and treatment.

Entities:  

Keywords:  BCG; Clinical trials; Immunology; Mycobacterium tuberculosis; Tuberculosis; Vaccines

Mesh:

Substances:

Year:  2018        PMID: 29601253      PMCID: PMC6067889          DOI: 10.1080/21645515.2018.1458806

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  200 in total

1.  Novel recombinant BCG coexpressing Ag85B, ESAT-6 and mouse TNF-alpha induces significantly enhanced cellular immune and antibody responses in C57BL/6 mice.

Authors:  Hongbo Shen; Chao Wang; Enzhuo Yang; Ying Xu; Wei Liu; Jingran Yan; Feifei Wang; Honghai Wang
Journal:  Microbiol Immunol       Date:  2010-08       Impact factor: 1.955

2.  Purification and characterization of a glucan from Bacillus Calmette Guerin and the antitumor activity of its sulfated derivative.

Authors:  Xiongbo Xu; Zixin Gu; Shao Liu; Na Gao; Xiaozhen He; Xiu Xin
Journal:  Carbohydr Polym       Date:  2015-04-22       Impact factor: 9.381

3.  Surface protein Adr2 of Rickettsia rickettsii induced protective immunity against Rocky Mountain spotted fever in C3H/HeN mice.

Authors:  Wenping Gong; Xiaolu Xiong; Yong Qi; Jun Jiao; Changsong Duan; Bohai Wen
Journal:  Vaccine       Date:  2014-02-28       Impact factor: 3.641

4.  Immunogenicity of an inactivated mycobacterial vaccine for the prevention of HIV-associated tuberculosis: a randomized, controlled trial.

Authors:  Jenni M Vuola; Matti A Ristola; Bernard Cole; Annika Järviluoma; Susan Tvaroha; Terhi Rönkkö; Outi Rautio; Robert D Arbeit; C Fordham von Reyn
Journal:  AIDS       Date:  2003-11-07       Impact factor: 4.177

5.  Recombinant BCG coexpressing Ag85B, ESAT-6 and mouse-IFN-gamma confers effective protection against Mycobacterium tuberculosis in C57BL/6 mice.

Authors:  Ying Xu; Bingdong Zhu; Qingzhong Wang; Jiazhen Chen; Yaqing Qie; Jiuling Wang; Hongyan Wang; Baolin Wang; Honghai Wang
Journal:  FEMS Immunol Med Microbiol       Date:  2007-10-04

6.  A single vaccination with protein-microspheres elicits a strong CD8 T-cell-mediated immune response against Mycobacterium tuberculosis antigen Mtb8.4.

Authors:  Jay T Evans; Jon R Ward; Jeff Kern; Mark E Johnson
Journal:  Vaccine       Date:  2004-05-07       Impact factor: 3.641

7.  A novel liposome adjuvant DPC mediates Mycobacterium tuberculosis subunit vaccine well to induce cell-mediated immunity and high protective efficacy in mice.

Authors:  Xun Liu; Zejiao Da; Yue Wang; Hongxia Niu; Ruiying Li; Hongjuan Yu; Shanshan He; Ming Guo; Yong Wang; Yanping Luo; Xingming Ma; Bingdong Zhu
Journal:  Vaccine       Date:  2016-02-02       Impact factor: 3.641

8.  Manipulation of immune responses to Mycobacterium bovis by vaccination with IL-2- and IL-18-secreting recombinant bacillus Calmette Guerin.

Authors:  Sarah Young; Michael O'Donnell; Euan Lockhart; Bryce Buddle; Lynn Slobbe; Yi Luo; Geoff De Lisle; Glenn Buchan
Journal:  Immunol Cell Biol       Date:  2002-06       Impact factor: 5.126

9.  Mycobacterium vaccae as adjuvant therapy to anti-tuberculosis chemotherapy in never-treated tuberculosis patients: a meta-analysis.

Authors:  Xiao-Yan Yang; Qun-Fei Chen; You-Ping Li; Si-Miao Wu
Journal:  PLoS One       Date:  2011-09-06       Impact factor: 3.240

10.  Out-of-Africa migration and Neolithic coexpansion of Mycobacterium tuberculosis with modern humans.

Authors:  Iñaki Comas; Mireia Coscolla; Tao Luo; Sonia Borrell; Kathryn E Holt; Midori Kato-Maeda; Julian Parkhill; Bijaya Malla; Stefan Berg; Guy Thwaites; Dorothy Yeboah-Manu; Graham Bothamley; Jian Mei; Lanhai Wei; Stephen Bentley; Simon R Harris; Stefan Niemann; Roland Diel; Abraham Aseffa; Qian Gao; Douglas Young; Sebastien Gagneux
Journal:  Nat Genet       Date:  2013-09-01       Impact factor: 38.330

View more
  22 in total

Review 1.  Peptide-Based Vaccines for Tuberculosis.

Authors:  Wenping Gong; Chao Pan; Peng Cheng; Jie Wang; Guangyu Zhao; Xueqiong Wu
Journal:  Front Immunol       Date:  2022-01-31       Impact factor: 7.561

2.  In silico Analysis of Peptide-Based Biomarkers for the Diagnosis and Prevention of Latent Tuberculosis Infection.

Authors:  Peng Cheng; Liang Wang; Wenping Gong
Journal:  Front Microbiol       Date:  2022-06-28       Impact factor: 6.064

3.  Pneumonia caused by Mycobacterium tuberculosis.

Authors:  Meili Wei; Jun Xi; Jun Wei; Bikui Tang
Journal:  Microbes Infect       Date:  2020-06-16       Impact factor: 2.700

4.  Tuberculosis: an ancient disease that remains a medical, social, economical and ethical issue.

Authors:  M Martini; N Riccardi; A Giacomelli; V Gazzaniga; G Besozzi
Journal:  J Prev Med Hyg       Date:  2020-04-30

5.  The Gap Between Global Tuberculosis Incidence and the First Milestone of the WHO End Tuberculosis Strategy: An Analysis Based on the Global Burden of Disease 2017 Database.

Authors:  Zhenyu Pan; Jun Zhang; Qingting Bu; Hairong He; Ling Bai; Jin Yang; Qingqing Liu; Jun Lyu
Journal:  Infect Drug Resist       Date:  2020-05-04       Impact factor: 4.003

Review 6.  The role of vaccines in fighting antimicrobial resistance (AMR).

Authors:  Kathrin U Jansen; Annaliesa S Anderson
Journal:  Hum Vaccin Immunother       Date:  2018-07-09       Impact factor: 3.452

7.  Challenges of Immune Response Diversity in the Human Population Concerning New Tuberculosis Diagnostics, Therapies, and Vaccines.

Authors:  Abul K Azad; Christopher Lloyd; Wolfgang Sadee; Larry S Schlesinger
Journal:  Front Cell Infect Microbiol       Date:  2020-04-08       Impact factor: 5.293

8.  Effects of Mycobacterium vaccae vaccine in a mouse model of tuberculosis: protective action and differentially expressed genes.

Authors:  Wen-Ping Gong; Yan Liang; Yan-Bo Ling; Jun-Xian Zhang; You-Rong Yang; Lan Wang; Jie Wang; Ying-Chang Shi; Xue-Qiong Wu
Journal:  Mil Med Res       Date:  2020-06-03

Review 9.  COVID-19 pandemic: SARS-CoV-2 specific vaccines and challenges, protection via BCG trained immunity, and clinical trials.

Authors:  Wenping Gong; Ashok Aspatwar; Shuyong Wang; Seppo Parkkila; Xueqiong Wu
Journal:  Expert Rev Vaccines       Date:  2021-06-15       Impact factor: 5.217

10.  Bacillus Calmette-Guérin (BCG) stimulates changes in dendritic cell surface marker expression in vitamin D-deficient mice.

Authors:  Huifeng Yang; Yang Zhan; Haotian Wu; Liangbi Xiang
Journal:  J Int Med Res       Date:  2020-03       Impact factor: 1.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.